A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.

被引：0
|
作者：
Pautier, Patricia
Floquet, Anne
Chevreau, Christine
Penel, Nicolas
Guillemet, Cecile
Delcambre, Corinne
Cupissol, Didier
Selle, Frederic
Isambert, Nicolas
Piperno-Neumann, Sophie
Saada-Bouzid, Esma
Bertucci, Francois
Bompas, Emmanuelle
Boudou-Rouquette, Pascaline
Collard, Olivier
Ly, Valerie Le Brun
Toulmonde, Maud
Le Cesne, Axel
Lacas, Benjamin
Duffaud, Florence
机构：
[1] Inst Gustave Roussy, Med Oncol Dept, Villejuif, France
[2] Inst Bergonie, Comprehens Canc Ctr, Bordeaux, France
[3] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[4] Ctr Oscar Lambret, Dept Med Oncol, Lille, France
[5] Ctr Henri Becquerel, Rouen, France
[6] Ctr Francois Baclesse, Caen, France
[7] Inst Canc Montpellier, Montpellier, France
[8] Tenon Hosp, Paris, France
[9] Ctr Georges Francois Leclerc, Dijon, France
[10] Inst Curie, Med Oncol Dept, Paris, France
[11] Univ Cote Azur, Ctr Antoine Lacassagne, Nice, France
[12] Inst Paoli Calmettes, Marseille, France
[13] Ctr Rene Gauducheau, Nantes, France
[14] Paris Univ, Cochin Hosp, Dept Med Oncol, Paris, France
[15] Inst Cancerol Loire, St Priest En Jarez, France
[16] CHU Dupuytren, Limoges, France
[17] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[18] Inst Gustave Roussy, Villejuif, France
[19] Gustave Roussy, Villejuif, France
[20] La Timone Univ Hosp, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11506
引用
收藏
页数：2
相关论文
共 25 条
  • [1] LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.
    Pautier, Patricia
    Floquet, Anne
    Cupissol, Didier
    Lacas, Benjamin
    Bompas, Emmanuelle
    Chevreau, Christine
    Selle, Frederic
    Weber, Beatrice E.
    Guillemet, Cecile
    Penel, Nicolas
    Duffaud, Florence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] LMS-02: A Phase II single-arm multicenter study to determine the efficacy of doxorubicin in combination with trabectedin as a 1st line treatment of metastatic and/or locally advanced leiomyosarcoma of uterine (U-LMS) or soft tissue (ST-LMS) origin: results of the soft tissue group
    Pautier, P.
    Chevreau, C.
    Le Cesne, A.
    Penel, N.
    Bui, B.
    Guillemet, C.
    Delcambre, C.
    Rey, A.
    Duffaud, F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S887 - S887
  • [3] Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
    Pautier, Patricia
    Floquet, Anne
    Chevreau, Christine
    Penel, Nicolas
    Guillemet, Cecile
    Delcambre, Corinne
    Cupissol, Didier
    Selle, Frederic
    Isambert, Nicolas
    Piperno-Neumann, Sophie
    Thyss, Antoine
    Bertucci, Francois
    Bompas, Emmanuelle
    Alexandre, Jerome
    Collard, Olivier
    Lavau-Denes, Sandrine
    Soulie, Patrick
    Toulmonde, Maud
    Le Cesne, Axel
    Lacas, Benjamin
    Duffaud, Florence
    [J]. LANCET ONCOLOGY, 2015, 16 (04): : 457 - 464
  • [4] Low skeletal muscle density as predictive for febrile neutropenia in patients treated by doxorubicin/trabcctedin/pegfilgrastim combination as a first line treatment of advanced or metastatic leiomyosarcoma (LMS) (LMS02 study).
    Antoun, Sami
    Floquet, Anne
    Penel, Nicolas
    Delcambre, Corinne
    Chevreau, Christine
    Cupissoi, Didier
    Alexandre, Jerome
    Duffaud, Florence
    Lacas, Benjamin
    Pautier, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as firstline therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
    Pautier, P.
    Italiano, A.
    Piperno-Neumann, S.
    Chevreau, C. M.
    Penel, N.
    Firmin, N.
    Rouquette, P. Boudou
    Bertucci, F.
    Le Brun-Ly, V.
    Ray-Coquard, I. L.
    Kalbacher, E.
    Bompas, E.
    Collard, O.
    Isambert, N.
    Guillemet, C.
    Rios, M.
    Le Cesne, A.
    Archambaud, B.
    Duffaud, F.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1030 - S1030
  • [6] LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
    Pautier, P.
    Italiano, A.
    Piperno-Neumann, S.
    Chevreau, C. M.
    Penel, N.
    Cupissol, D.
    Rouquette, P. Boudou
    Bertucci, F.
    Balleyguier, C.
    Lebrun-Ly, V.
    Blay, J-Y.
    Kalbacher, E.
    Delcambre, C.
    Bompas, E.
    Collard, O.
    Isambert, N.
    Guillemet, C.
    Rios, M.
    Sundqvist, M.
    Duffaud, F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1335 - S1336
  • [7] A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
    Pautier, P.
    Floquet, A.
    Chevreau, C.
    Penel, N.
    Guillemet, C.
    Delcambre, C.
    Cupissol, D.
    Selle, F.
    Isambert, N.
    Piperno-Neumann, S.
    Saada-Bouzid, E.
    Bertucci, F.
    Bompas, E.
    Alexandre, J.
    Collard, O.
    Lebrun-Ly, V.
    Soulier, P.
    Toulmonde, M.
    Le Cesne, A.
    Lacas, B.
    Duffaud, F.
    [J]. ESMO OPEN, 2021, 6 (04)
  • [8] RANDOMIZED, OPEN, PROSPECTIVE, PHASE II CLINICAL TRIAL OF DOXORUBICIN (DOXO) VS. TRABECTEDIN PLUS DOXO IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED NON-OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS (STS): GEIS-20 STUDY
    Martin Broto, J.
    Garcia Del Muro, X.
    Lopez-Pousa, A.
    De Las Penas, R.
    Maurel, J.
    Cubedo, R.
    Redondo, A.
    Martinez-Trufero, J.
    Cruz Jurado, J.
    Poveda, A. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 490 - 490
  • [9] A prospective, single-arm phase II study of pegylated-liposome doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma
    Liu, X.
    Zhang, X.
    Cao, J.
    Wang, H.
    Wu, X.
    Luo, Z.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S986 - S986
  • [10] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
123